tirzepatide surpass Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Incidence of mild and severe

Body weight and metabolic status also affect GLP-1 production

Tirzepatide may also help some people experience less pain by reducing body weight and pressure on weight-bearing joints

Heres what experts had to say about the preliminary data and why tirzepatide could be a useful tool for protecting heart health

Trump drug executive order could cut prices of Wegovy, Zepbound The intrigue: President Trump signed an executive order Monday that focuses on lowering drug prices

5 Users have 4 times greater risk for stomach paralysis and bowel obstructions and 9 times greater risk for pancreatitis

Discuss with your provider if you are planning pregnancy